The current inhibitors against SGLT2, such as dagliflozin, enagliflozin, and sotagliflozin, have cardioprotective effects and have been used in the treatment of heart failure (Zannad et al., 2020; Petrie et al., 2020; Bhatt et al., 2021). The gene discussed is SLC5A2; the disease is heart failure.